Subject Review: Attention and memory dysfunction after traumatic brain injury: cholinergic mechanisms, sensory gating, and a hypothesis for further investigation
D Arciniegas, MD, L Adler, MD, J Topkoff… - Brain Injury, 1999 - Taylor & Francis
Traumatic brain injury TBI is a common occurrence, with a rate of nearly 400 000 new
injuries per year. Cognitive and emotional disturbances may become persistent and …
injuries per year. Cognitive and emotional disturbances may become persistent and …
Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia
H Tohgi, T Abe, M Kimura, M Saheki… - Journal of neural …, 1996 - Springer
The acetylcholine (ACh) and choline (Ch) concentrations in the cerebrospinal fluid were
investigated in patients with vascular dementia of the Binswanger type (VDBT) or multiple …
investigated in patients with vascular dementia of the Binswanger type (VDBT) or multiple …
Substituted spiro [2.3′] oxindolespiro [3.2 ″]-5, 6-dimethoxy-indane-1 ″-one-pyrrolidine analogue as inhibitors of acetylcholinesterase
Series of pyrolidine analogues were synthesized and examined as acetylcholinesterase
(AChE) inhibitors. Among the compounds, compounds 4k and 6k were the most potent …
(AChE) inhibitors. Among the compounds, compounds 4k and 6k were the most potent …
Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors
The function of the cholinergic system is known to change during normal aging and in
pathological conditions such as Alzheimer's disease. The present study was designed to …
pathological conditions such as Alzheimer's disease. The present study was designed to …
Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease
WJ Krall, JJ Sramek, NR Cutler - Annals of …, 1999 - journals.sagepub.com
OBJECTIVE: To provide a review of acetylcholinesterase inhibitors (AChEIs) tested as
therapeutic agents for Alzheimer disease (AD). DATA SOURCES: MEDLINE searches …
therapeutic agents for Alzheimer disease (AD). DATA SOURCES: MEDLINE searches …
Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development
Human cytochrome P450 1A2 (CYP1A2) is one of the major CYPs in the liver (&sim13%)
and metabolizes about 20% of clinically used drugs. CYP1A2 is a 515-residue protein with a …
and metabolizes about 20% of clinically used drugs. CYP1A2 is a 515-residue protein with a …
Pharmacological profile of huperzine A, a novel acetylcholinesterase inhibitor from Chinese herb
XC Tang, YF Han - CNS Drug Reviews, 1999 - repository.ust.hk
HupA, a novel alkaloid isolated from the Chinese medicinal herb Huperzia serrata, is a
reversible, potent, and selective inhibitor of AChE. Compared with other well-known AChEIs …
reversible, potent, and selective inhibitor of AChE. Compared with other well-known AChEIs …
Cholinergic strategies for Alzheimer's disease
Alzheimer's disease is a devastating degenerative disorder of the central nervous system
that results in gradual deterioration of cognitive function and severe alteration of personality …
that results in gradual deterioration of cognitive function and severe alteration of personality …
Cholinesterase inhibitors stabilize Alzheimer's disease
E Giacobini - Annals of the New York Academy of Sciences, 2000 - Wiley Online Library
During the last decade, a systematic effort to develop a pharmacological treatment for
Alzheimer disease (AD) has resulted into three drugs being registered for the first time in the …
Alzheimer disease (AD) has resulted into three drugs being registered for the first time in the …
Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study
DI Kaufer, JL Cummings… - Journal of geriatric …, 1996 - journals.sagepub.com
We conducted an open-label study designed to assess the effects of tacrine on behavioral
changes in patients with Alzheimer's disease (AD). Twenty-eight subjects completed a …
changes in patients with Alzheimer's disease (AD). Twenty-eight subjects completed a …